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Timing of palliative care referral and
aggressive cancer care toward the end-oflife in pancreatic cancer: a retrospective,
single-center observational study
Natasha Michael1,2,3* , Greta Beale2, Clare O’Callaghan1,4,5, Adelaide Melia1, William DeSilva3, Daniel Costa6,7,
David Kissane3,8, Jeremy Shapiro3 and Richard Hiscock9

Abstract
Background: Pancreatic cancer is noted for its late presentation at diagnosis, limited prognosis and physical and
psychosocial symptom burden. This study examined associations between timing of palliative care referral (PCR) and
aggressive cancer care received by pancreatic cancer patients in the last 30 days of life through a single health service.
Method: A retrospective cohort analysis of end-of-life (EOL) care outcomes of patients with pancreatic cancer who died
between 2012 and 2016. Key indicators of aggressive cancer care in the last 30 days of life used were: ≥1 emergency
department (ED) presentations, acute inpatient/intensive care unit (ICU) admission, and chemotherapy use. We
examined time from PCR to death and place of death. Early and late PCR were defined as > 90 and ≤ 90 days
before death respectively.
Results: Out of the 278 eligible deaths, 187 (67.3%) were categorized as receiving a late PCR and 91 (32.7%) an
early PCR. The median time between referral and death was 48 days. Compared to those receiving early PCR, those with
late PCR had: 18.1% (95% CI 6.8–29.4%) more ED presentations; 12.5% (95% CI 1.7–24.8%) more acute hospital admissions;
with no differences in ICU admissions. Pain and complications of cancer accounted for the majority of overall ED
presentations. Of the 166 patients who received chemotherapy within 30 days of death, 23 (24.5%) had a late PCR
and 12 (16.7%) an early PCR, with no association of PCR status either unadjusted or adjusted for age or gender.
The majority of patients (55.8%) died at the inpatient palliative care unit.
Conclusion: Our findings reaffirm the benefits of early PCR for pancreatic cancer patients to avoid inappropriate
care toward the EOL. We suggest that in modern cancer care, there can sometimes be a need to reconsider the
use of the term ‘aggressive cancer care’ at the EOL when the care is appropriately based on an individual patient’s
presenting physical and psychosocial needs. Pancreatic cancer patients warrant early PCR but the debate must thus
continue as to how we best achieve and benchmark outcomes that are compatible with patient and family needs and
healthcare priorities.
Keywords: Pancreatic cancer, End-of-life, Palliative care, Place of death, Aggressive cancer care
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Background
A diagnosis of pancreatic cancer is unsettling for patients
and their families, with late presentations at diagnosis and
new therapeutic agents offering only modest improvements
in survival [1, 2]. The median overall survival of metastatic
pancreatic cancer is 8–11 months and the median overall
survival of locally advanced (but not metastatic) inoperable
pancreatic cancer is 12–14 months [3, 4]. Currently, less
than 5–7% of Australians diagnosed with metastatic disease
survive beyond five years [5]. Patients often experience significant physical symptom burden, treatment side effects,
and psychosocial burden leading to depression and anxiety
[6]. Despite pancreatic cancer being the fourth leading
cause of cancer death in the United States of America [7]
and Europe [8] and the fifth leading cause of cancer death
in Australia [9], few studies have examined the impact of
palliative care on the quality of end-of-life (EOL) care received in this patient cohort [10, 11].
Quality EOL indicators to evaluate the use of aggressive
treatments toward the EOL for cancer patients are increasingly recommended and endorsed by peak bodies, including the National Quality Forum [12] and the American
Society of Clinical Oncology (ASCO) Quality Oncology
Practice Initiative [13]. Traditionally, aggressive cancer care
received toward the EOL can be defined as any of the
following: use of chemotherapy in the last 14 [14] or 30
days [11] of life, emergency department (ED) presentation,
acute hospital/intensive care unit (ICU) admission within
30 days of death or death in ICU, and late referral to hospice/palliative care services (≤3 months from referral to
death) [15, 16]. Studies have shown that cancer patients
experience more aggressive treatments toward the EOL
when they are younger, diagnosed with hematological cancers, have distant metastatic disease, poor prognostic
tumors, and are managed by oncologists and in teaching
hospitals [11, 17, 18].
EOL care however, is enhanced in cancer patients when
palliative care is integrated early and provided for a longer
duration, particularly after discontinuing chemotherapy
[19]. Nonetheless, reports of chemotherapy use for
patients with varied cancer diagnoses within the last
month of life remains wide-ranging from less than 8 to
45.5% [11, 20, 21]. A retrospective cohort study of 366
cancer patients found that those referred early to palliative
care benefited at the EOL through more hospice inpatient
utilization (74% versus 47%, adjusted p < 0.001) [22] and
fewer emergency room visits (39% vs. 68%, p < 0.001), hospitalizations (48% vs. 81%, p < 0.003) and hospital deaths
(17% vs. 31%, p = 0.004) in the last 30 days of life. Furthermore, when EOL care planning discussions occurred,
patients received less acute care within 30 days of death
(OR: 0.67; p = 0.025) [15].
Data relating specifically to the use of aggressive treatments toward the EOL for pancreatic cancer patients
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remain limited. American surveillance data (comparing
data from 1992 to 1994 and 2004–2006) has shown that
despite an increase in hospice enrollment of pancreatic
cancer patients, admissions to ICU and chemotherapy
use in the last month of life increased significantly from
15.5 to 19.6% (p < 0.0001) and 8.1 to 16.4% (p < 0.0001)
respectively [23]. A Swiss study of 231 pancreatic cancer
patients similarly showed that 24% of patients received
chemotherapy in the last 4 weeks of life, with the median
survival from last chemotherapy to death being 7.5
weeks (95% CI 6.7–8.4) [24]. Conversely a retrospective
population cohort study of 5381 Canadian patients
with advanced pancreatic cancer found that PCR was
associated with less chemotherapy treatment (OR 0.34,
95% CI 0.25–0.46), fewer ICU admissions (OR 0.12,
95% CI 0.08–0.18), reduced emergency department
visits (OR 0.19, 95% CI 0.16–0.23), and fewer hospitalizations near death (OR 0.24, 95% CI 0.19–0.31) [10].
Similarly, a Taiwanese study showed that pancreatic
cancer patients receiving inpatient palliative care compared to acute hospital care were more likely to receive
opioids (84.4% vs. 56.5%, respectively; p < 0.001), had
shorter acute hospital stays (10.6 ± 11.1 days vs. 20.6 ± 16.3
days, respectively; p < 0.001), fewer aggressive procedures,
and lower medical costs (both, p < 0.005) [25].
The poor survival outcomes and high symptom burden
experienced in pancreatic cancer makes it the ideal prototype cancer to study the quality of EOL care. This study,
conducted at a single health service, aimed to examine
associations between timing of PCR and aggressive cancer
care received by pancreatic cancer patients in the last 30
days of life.

Methods
Design

We conducted a retrospective observational study of a
prevalent cohort of all patients registered with a diagnosis
of pancreatic cancer between January 2012 and December
2016 in a single institution. We included patients over the
age of 18 who were registered patients with Cabrini Health,
who had received a referral to the palliative care service
and who subsequently died. Follow up data was available
until March 2017. Ethics approval was obtained from
Cabrini Health’s Human Research Ethics Committee
(Number: 06–19–06-17). The hospital’s administration provided consent to review patient records and utilize data for
the purpose of this study. The Strobe statement was used
as a guideline in preparation of this manuscript [26].
Setting

The data was obtained from a large not-for-profit, private
health care service providing acute, sub-acute and community based care across six campuses in Melbourne,
Australia. The Health Service has 31 accredited medical
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oncologists consulting across two sites, both providing
chemotherapy services through day oncology clinics. In
2016, there were 3398 new cancer diagnoses registered,
along with 24,551 same day and 9367 overnight episodes
of care. Specialist palliative care is provide via a large integrated service incorporating a 22 bed inpatient unit, community service, supportive care clinics and consult
services at no cost to the patient.
Data sources and outcomes

The hospital’s administrative database was used to identify
eligible patients using the International Classification of
Diseases [27] Code C25.0 to C25.9 and who had a death
registered on the database (C25.0-C25.9 describes the diagnosis ‘malignant neoplasm of pancreas’ in more detail).
Confirmatory data on further deaths were obtained through
the state department’s register of deaths. We captured basic
demographic variables (age, sex, country of birth, date and
place of death).
Clinical electronic and written case records and the hospital chemotherapy drug administration database were subsequently examined to identify key indicators of aggressive
cancer care in the last 30 days of life which included: intravenous chemotherapy use, multiple emergency department
presentations and acute hospital admission (defined as ≥1),
or intensive care admission (≥ 1). We included chemotherapy administration in external hospitals if these data were
available in the clinical records, as patients may have
chosen to receive treatment elsewhere. We further determined if referral to the hospitals’ palliative care service had
occurred, the interval between referral to palliative care and
death, and the place of death. We choose to define early
palliative care based on the duration of continuity of palliative care before death [15]. Thus early and late PCR were
defined as more than 90 days and less than or equal to 90
days before death respectively.

Statistical analysis
Summary measures of patients’ socio-demographic characteristics were presented as mean (SD), median [25th - 75th
percentile] or number (%) according to type and distribution. Unadjusted associations between PCR and measures
of aggressive cancer care and place of death used likelihood ratio chi-squared statistic based on a univariable logistic model, and the associations were also tested using a
multivariable logistic model to adjust for age and gender.
Strength of association is presented as either odds ratio
(OR) or risk difference (RD) and the associated 95% confidence interval. There was no missing data except for four
patient files which did not have information on chemotherapy usage. No imputations were made. The two-sided
significance level was set at 0.05 and no adjustment was
made for multiple comparisons. Statistical analysis was
performed using Stata v 15 statistical software [28].
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Results
We identified 457 patients with a diagnosis of pancreatic
cancer over the study period. Of these, 278 met the eligibility criteria of being registered with the health service with a
diagnosis of pancreatic cancer, receiving a referral to the
hospital’s palliative care service, more than 18 years of age
and dying within the study period. Patient characteristics by
PCR status are presented in Table 1. Compared to patients
receiving late PCR those with an early PCR were younger,
with mean difference 5.1 (95%CI 2.2 to 8.0) years. The
median time between referral and death was 48 days, with
187/278 (67.3%) of patients categorized as receiving a late
PCR and 91/278 (32.7%) receiving an early PCR.
Emergency department presentation, acute hospital
and intensive care unit admission.
Measures of aggressiveness of cancer care are summarized in Table 2. One hundred and one (36.3%) patients
presented to the ED within the last 30 days of life and, of
these, 15 (14.9%) had more than one admission. Those with
Table 1 Patient characteristics by palliative care referral
Palliative Care Referral
(Days before death)
Characteristic

Early
(> 90 days)

Late
(≤ 90 days)

p-value

(n = 91)

(n = 187)

Age (years)

73 (11.6)

78 (11.7)

< 0.001

Gender (male)

40 (44.0%)

95 (50.8%)

0.28

Married

59 (64.8%)

110 (58.8%) 0.11

Widowed

18 (19.8%)

47 (25.1%)

Single

7 (7.7%)

11 (5.9%)

Divorced / Separated

7 (7.7%)

10 (5.4%)

Defacto

0

7 (3.7%)

Unknown

0

2 (1.1%)

58 (63.7%)

122 (65.3%) 0.83

Marital Status

Place of Birth
Australia / New Zealand
United Kingdom / Ireland

9 (9.9%)

15 (8.0%)

Other European Countries

14 (15.4%)

32 (17.1%)

Asia

2 (2.2%)

6 (3.2%)

Others

8 (8.8%)

11 (5.9%)

Unknown

0

1 (0.5%)

Time between Palliative Care
referral and death
Median [25th - 75th percentile] 177 [133–295] 26 [11–49]
days
Place of Death
Palliative Care Unit

50 (18%)

105 (37.8%) 0.98

Acute Hospital

22 (7.9%)

44 (15.8%)

Home/Residential Care Facility

19 (6.8%)

38 (13.7%)

Data presented as mean (SD), median [25th – 75th percentile] or count %
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Table 2 Aggressiveness of care in the last 30 days of life for 278 patients with pancreatic cancer
Palliative Care Referral (Days Before Death)
Early (> 90 days)

Late (≤ 90 days)

N = 91

N = 187

Total number of patients

22 (24.2%)

79 (42.2%)

0.003

No of patients presenting once

19 (86.3%)

67 (84.8%)

0.57a

No of patients presenting twice

2 (9.1%)

11 (13.9%)

p-value

Emergency Department (ED) Presentations
No of ED presentations

No of patients presenting thrice

1 (4.6%)

1 (1.3%)

Total number of presentations

26

92

Pain

9 (34.6%)

19 (20.7%)

Nausea/Vomiting

1 (3.8%)

16 (17.4%)

Confusion

1 (3.8%)

8 (8.7%)

Other Symptoms

7 (26.9%)

8 (8.7%)

Infection

3 (11.5%)

8 (8.7%)

Complications of Cancer

6 (23.1%)

22 (23.9%)

Reason for ED presentation (based upon all
presentations in last 30 days of life)b

Investigations and Procedures

0

1 (1.1%)

Funtional decline

0

4 (4.3%)

Other medical problems

0

9 (9.8%)

End of life care

1 (3.8%)

0

Admit to acute hospital

18 (81.8%)

66 (83.6%)

Discharge home from ED

1 (4.6%)

8 (10.1%)

Transfer to palliative care unit

0

2 (2.5%)

Death in ED

3 (13.6%)

3 (3.8%)

Total number of patients

48 (52.8%)

122 (65.2%)

0.04

0

43 (47.3%)

65 (34.7%)

0.009

1

47 (51.6%)

104 (55.6%)

2

1 (1.1%)

16 (8.6%)

3

0

2 (1.1%)

Total admission episodes

49

142

Discharge home from ward

12 (24.5%)

48 (33.8%)

Transfer to palliative care unit

19 (38.8%)

55 (38.7%)

Outcome of ED presentation
0.26

Acute Hospital Admissions by Patient
No of acute hospital admission

Outcome of acute hospital admission (total
admission episodes)

Transfer to another hospital

0

2 (1.4%)

Death on ward

18 (36.7%)

37 (26.1%)

0.31
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Table 2 Aggressiveness of care in the last 30 days of life for 278 patients with pancreatic cancer (Continued)
Palliative Care Referral (Days Before Death)

Intensive Care Admission

Early (> 90 days)

Late (≤ 90 days)

N = 91

N = 187

1 (1.1%)

2 (1.1%)

0.98

73 (80.2%)

97 (51.9%)

< 0.001

12/72 (16.7%)

23/94 (24.5%)

0.22

p-value

Chemotherapy Use
Received any chemotherapyc
d

Received Chemotherapy < 30 days

Data presented as number (%)
a
Testing hypothesis of a difference in number of presentations, in patients who present to ED.
b
Patients may present with ≥1 reason to ED
c
Figures relate to any chemotherapy, not just < 30 days
d
Excludes 4 patients with unknown chemotherapy status

a late PCR were 18.1% (95%CI 6.8–29.4%, p = 0.003) more
likely to have an ED presentation than those with an early
PCR. Reasons for ED presentation were widely varied
(see Table 2) with main reasons including pain, nausea,
vomiting and complications of cancer (e.g. biliary obstruction and ascites) and infection. One hundred and seventy
(61.2%) patients had an admission to the acute hospital in
the last 30 days of life, with 19 (6.8%) having more than one
admission. There is moderate evidence that late PCR is
associated with a 12.5% (95%CI 1.7–24.8%, p = 0.04) higher
acute hospital admission rate compared to early PCR
(Table 3). Furthermore, the number of admission episodes
is increased in those receiving late PCR compared to those
Table 3 Odds ratios (OR) for aggressive management
comparing late to early (referent level) Palliative Care referral
OR (95%CI, p- value)
Unadjusted

Adjusted for
age & gender

Emergency Department
presentation

2.29 (1.31
to 4.02,
p = 0.004)

1.92 (1.08
to 3.42,
p = 0.03)

Acute Hospital Admission

1.68 (1.01
to 2.80,
p = 0.05)

1.60 (0.95
to 2.69
p = 0.08)

Intensive Care Admission

0.97 (0.09
to 10.90,
p = 0.98)

1.09 (0.09
to 12.74,
p = 0.94)

Received any Chemotherapy

0.27 (0.15
to 0.48,
p < 0.001)

0.33 (0.17
to 0.66,
p < 0.002)

Received Chemotherapy
< 30 days before death

1.6 (95%CI
0.74 to
3.53, p = 0.22)

1.7 (95%CI
0.75 to 3.7,
p = 0.21)

Palliative Care Unit
(referent level)

1

1

Home / RCAF

1.00 (0.47 to
2.12, p = 0.99)

1.06 (0.48 to
2.32, p = 0.88)

Acute Hospital

1.05 (0.57 to
1.94, p = 0.88)

1.11 (0.59 to
2.09, p = 0.76)

receiving early PCR in the last 30 days of life (Table 2).
Based upon a total of 191 admission episodes, 31.4% were
discharged home, 38.7% transferred to an inpatient palliative care unit and 28.8% died in hospital. Only 3 (1.1%) patients had an ICU admission in the last 30 days of life and
there were no deaths in the ICU. There was also no association between the timing of PCR and patients’ place of
death (Table 3).
Chemotherapy use

Details of chemotherapy use are summarized in Fig. 1.
Overall 170 (61.2%) patients were recorded as having
received intravenous chemotherapy at any one time during
the study period. Those patients with early PCR were more
likely to receive chemotherapy at any time compared to
those with late PCR [risk difference 28.3% (95%CI 17.4 to
39.2, p < 0.001)] (Table 3). Overall, 108 (38.8%) did not
receive chemotherapy due to advanced nature of the illness
at diagnosis, high risk due to comorbidities or patient
refusal. Details for the use of chemotherapy within 30 days
of death was available for 166 patients. Twenty-three
patients (24.5%) received chemotherapy with late PCR and

Place of death

Fig. 1 Chemotherapy use in the last 30 days of life
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12 (16.7%) with early PCR within 30 days of death. There
was no association of chemotherapy usage within 30 days
of death and PCR status either unadjusted or adjusted for
age or gender (Table 3).

Discussion
This is the first Australian study to examine EOL outcomes in a cohort of pancreatic cancer patients referred
to a palliative care service and its association with timing
of PCR. Given that a recent systematic review demonstrated a 98% loss of healthy life in pancreatic cancer
patients [29], it is paramount that due vigilance is given to
the EOL care experience of patients and caregivers. The
ASCO practice guidelines for metastatic pancreatic cancer
recognizes palliative care as an important adjunct in management and recommends early initiation of a referral,
preferably at the first visit [6]. This recommendation is further validated by findings from a recent multicenter Delphi
study undertaken to establish an international core set of
patient reported outcomes (PROs) in pancreatic cancer
[30]. Eight PRO’S rated as ‘very important’ by patients
(curative- and palliative-setting) and health care professionals were: general quality of life, general health,
physical ability, ability to work/do usual activities, fear
of reoccurrence, satisfaction with services/care organizations, abdominal complaints (pain/discomfort) and
relationship with partner/family.
There remains ambiguity as to what constitutes an
early referral to palliative care, with figures ranging from
> 3 months before death [15, 22, 31] to 6–14 months
prior to death [32]. Only a third of our patient cohort
(32.7%) received an early PCR (> 3 months before death).
This compares to 10.1% of 922 [31] and 33% of 366
[15] patients with all cancer types in single American
institutions. Additionally our median time between referral to death was 48 days. This compared to Bennett et
al. who found the median duration of palliative care
involvement before death across 3 services in the United
Kingdom was 37 days, with differences in duration identified between cancer and non-cancer patients (16 versus
22 days) and setting of care (community or the acute
hospital; 22 days versus 13 days). There was a statistical
difference (p = < 0.001) between cancer types, with prostate or breast cancer having the longest time (median days
of 43.5 and 48 days respectively) and hematological and
head and neck cancers having the shortest time (median
26 days) [32]. A similar retrospective Irish study conducted
across an integrated palliative care service found that mean
time from referral to death interval was 70 days, with the
majority receiving care across more than one setting [33].
Studies have also demonstrated that longer referral-to
death interval increases likelihood of dying at home or in
an inpatient hospice [34] and the intensity of palliative care
follow up is associated with fewer instances of aggressive
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treatments used near death, with the minimum number of
palliative care contacts needed to benefit ranging between
three and four [10]. Additionally, home has been shown to
be the preferred place of death for the majority of cancer
patients [35] and those never admitted to an inpatient
palliative care unit, whilst those with at least one admission
to an inpatient palliative care unit have shown preference
for care in this setting [32]. Despite our findings demonstrating no association between timing of PCR and
place of death, the majority (55.8%) of patients died in
the inpatient palliative care unit, with only a fifth
(20.5%) dying at home/residential care facility. We did
not collect data on the intensity of palliative care follow
up following referral that may have influenced this outcome. In this cohort with pancreatic cancer, the location
for death for a pancreatic cancer patient may have been
influenced by poorly controlled symptoms and complications of cancer as detailed in Table 2, necessitating the
availability of expert care. The additional perceived burden
on others and security with the familiarity of staff and environment [36] may have been contributing factors. Our
high death rates in the inpatient palliative care unit may
also be attributed to our model of early integration palliative care [37], which facilitates admission for symptom control and rehabilitation through the illness trajectory and not
simply EOL care. 38.7% of those admitted into hospital
were subsequently transferred to the inpatient palliative
care unit, thus increasing the likelihood of patients having
one or more admissions to an inpatient palliative care unit
pre-death, possibly influencing preference for care in the
this setting toward the EOL.
When evaluating quality indicators for care of cancer
patients in their last days of life, Raijmakers et al. found
that > 80% of respondents agreed that < 4% of patients
who die should have > 1 ED visit, > 1 hospitalizations or
have an ICU admission in the last 30 days [38]. Our
findings were contrary to these recommendations, with
just over a third (36.3%) of patients presenting to the ED
and close to two thirds (61.2%) having an acute hospital
admission in the last 30 days of life. Additionally, 14.9%
had > 1 ED presentations and 6.8% > 1 hospital admission. Nonetheless, ED presentations and hospital admissions remain common in patients with advanced cancer.
A systematic review and meta-analysis of 30 studies by
Henson et al. examined ED attendance by cancer patients in their last month of life [39]. It described contributing demographic, clinical and environmental variables
that increased the likelihood of ED presentations which
included being male and of black race, having lung cancer,
lower socioeconomic status and without a PCR [39].
Worsening symptoms, treatment toxicity and caregiver
stress have also been shown to contribute to ED visits [40]
as found in our study (Table 2). Nonetheless, our findings
supported the findings of Hui et al. [15], confirming
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benefits of early palliative care, with a late PCR increasing
the likelihood of ED presentations and number of hospital
admissions in this cohort.
These contradictory findings of seemingly aggressive
cancer care supports the findings of Wijnhoven et al. who
in a qualitative study exploring the impact of incurable
cancer (pancreatic and non-small cell lung cancer) on
family members and primary care-givers suggests that ED
presentations and hospital admission may be considered
to be part of necessary treatment as opposed to avoidable
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burdens [41]. Figure 2 demonstrates the integrated model
of care at the study site, demonstrating how symptom
complexity, psychosocial distress, lack of inpatient palliative care beds or staffing may lead to ED or acute hospital
presentations. Patient and caregiver strain can be significant when patients experience the array of symptoms and
complications that may arise with pancreatic cancer as
shown in our findings. Pain is associated with reduced
survival in pancreatic cancer and affects up to 80% of
patients, with 50% requiring strong opioid analgesia [42].

Fig. 2 Patient flow through an integrated model of care Images depicted in Fig. 2 were adapted from icons by Freepik, Smartline and
Smashicons from www.flaticon.com
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Depression together with anxiety affects 33–50% of patients [43], influencing overall quality of life and the social,
emotional and functional wellbeing of both patient and
caregiver. Complications may include obstruction, ascites
and thromboembolism [6], all of which cause significant
symptomology and require acute medical intervention.
Finally, the use of chemotherapy in situations that are
deemed futile remains common in cancer, with its use
sometimes being justified as a means to reinforce hope
in dire situations [44]. This collusion of hope may be
unnecessary if honest conversations and early involvement of palliative care service are used to assist patients
and families come to terms with the inevitable outcome. In our study, we failed to categorize the cohort
to those with potentially curable, locally advanced or
metastatic disease and failed to exclude those with a
diagnosis of an additional cancer. These factors may
have contributed to chemotherapy use in the small cohort of 35 (20.6%) of the 170 patients who received
treatment in the last 30 days of life.

Conclusion
Our findings mirror the results of a small number of
international studies and reaffirm the benefits of
early referral to palliative care for pancreatic cancer
patients to avoid futile treatment and inappropriate
care toward the EOL [10, 23, 25]. We however question the current benchmarks for aggressive cancer
care at the EOL, based on our findings that patients
with significant symptoms and whose caregivers lack
support appropriately require acute hospital service
utilization or care in a supported environment. We
suggest that in modern cancer care, there can sometimes be a need to reconsider the use of the term
‘aggressive cancer care’ at the EOL when the care is
appropriately based on an individual patient’s presenting physical and psychosocial need [45]. For pancreatic cancer patients, the wide spectrum of
significant symptomology experienced and the condensed time frame associated with the diagnosis may
appropriately justify the use of acute services and
treatments at this point of life.
Ironically, the widespread use of what is traditionally
described as aggressive treatments in the final month of
life may paradoxically rise with palliative care integration earlier in the disease trajectory and into the acute
setting, as symptom burden is appropriately managed,
unless outreach community services develop alternate
solutions to reduce hospital presentations and maintain
care in the community. The debate must thus continue
as to how we best achieve and benchmark outcomes
that are compatible with patient and family needs, informed views, experiences and healthcare priorities.
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